<p>哈德逊湾资本管理公司在最近向证券交易委员会提交的文件中表示，在第四季度将其在武田制药有限公司（NYSE:TAK - 免费报告）的持股比例提高了 10.0%。该公司在季度内购买了额外的 25,000 股后，持有该公司 275,000 股股票。截至其最近向证券交易委员会提交的文件，哈德逊湾资本管理公司在武田制药的持股价值为 3,641,000 美元。</p>
<p>获取 <strong>武田制药</strong> 的提醒：</p>
<ul>
<li>分析师预测 Wave Life Sciences 在降息后有 85% 的上涨空间</li>
</ul>
<p>其他一些机构投资者最近也买卖了该股票的股份。Farther Finance Advisors LLC 在第四季度将其在武田制药的持股比例提高了 123.6%。Farther Finance Advisors LLC 现在拥有 3,575 股该公司的股票，价值 47,000 美元，在此期间又购买了 1,976 股。Crowley Wealth Management Inc.在第四季度获得了武田制药的新头寸，价值约 52,000 美元。Cromwell Holdings LLC 在第四季度获得了武田制药的新头寸，价值约 61,000 美元。Venturi Wealth Management LLC 在第四季度将其在武田制药的持股比例提高了 554.7%。Venturi Wealth Management LLC 现在拥有 5,028 股该公司的股票，价值 67,000 美元，在上个季度又购买了 4,260 股。最后，Lindbrook Capital LLC 在第四季度将其在武田制药的持股比例提高了 65.0%。Lindbrook Capital LLC 现在拥有 5,151 股该公司的股票，价值 68,000 美元，在此期间又购买了 2,029 股。对冲基金和其他机构投资者持有该公司 9.17% 的股票。</p>
<h2>武田制药股价下跌 1.4%</h2>
<p>NYSE TAK 的股票在周二开盘价为 14.17 美元。该公司的流动比率为 1.31，速动比率为 0.72，债务与股本比率为 0.63。武田制药有限公司的股价在一年内最低为 12.58 美元，最高为 15.43 美元。该公司的 50 日移动平均价格为 14.86 美元，200 日移动平均价格为 14.00 美元。该公司的市值为 450.7 亿美元，市盈率为 35.41，市盈增长比率为 0.24，贝塔值为 0.26。</p>
<ul>
<li>现在是购买这三家提高收入指引的医疗公司吗？</li>
</ul>
<p>武田制药（NYSE:TAK - 获取免费报告）最近在 5 月 8 日星期四发布了季度财报。该公司报告季度每股收益为 0.16 美元，低于市场共识预期的 0.24 美元，差距为 0.08 美元。武田制药的股本回报率为 9.39%，净利润率为 4.53%。该公司季度收入为 73.4 亿美元，而分析师预期为 80.2 亿美元。整体来看，分析师预测武田制药有限公司在当前财政年度的每股收益为 1.64 美元。</p>
<h2>华尔街分析师的看法</h2>
<p>另外，摩根士丹利在 4 月 2 日星期三的一份研究报告中将武田制药的评级从 “持平” 上调至 “增持”。</p>
<ul>
<li>价格增长与收益：为了那种神奇的组合，离开美国。</li>
</ul>
<p><strong>查看我们关于武田制药的最新股票报告</strong></p>
<h2>武田制药公司简介</h2>
<p>（免费报告）</p>
<p>武田制药有限公司从事药品的研究、开发、生产、营销和外部授权，业务遍及日本及国际市场。它在胃肠病、罕见疾病、血浆衍生疗法、免疫学、肿瘤学和神经科学等领域提供药品。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票超过武田制药</li>
<li>每月分红股票的利弊</li>
<li>Palantir 的最新交易可能会冻结其股价</li>
<li>交易股票：相对强弱指数及其用途</li>
<li>4 家汽车制造商股票对关税的反应：赢家与输家</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>这就是为什么期权交易者喜欢 Dutch Bros 股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRBSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRBSw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在武田制药吗？</h2>
<p>在你考虑武田制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而武田制药并不在名单上。</p>
<p>虽然武田制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

4502

<p>根据 Hudson Bay Capital Management LP 最近向证券交易委员会提交的文件，该公司在第四季度将其在武田药品工业株式会社（NYSE:TAK - 免费报告）的持股比例提高了 10.0%</p>

<p>Hudson Bay Capital Management LP lifted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 10.0% in the fourth quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 275,000 shares of the company's stock after purchasing an additional 25,000 shares during the quarter. Hudson Bay Capital Management LP's holdings in Takeda Pharmaceutical were worth $3,641,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>哈德逊湾资本管理公司在最近向证券交易委员会提交的文件中表示，在第四季度将其在武田制药有限公司（NYSE:TAK - 免费报告）的持股比例提高了 10.0%。该公司在季度内购买了额外的 25,000 股后，持有该公司 275,000 股股票。截至其最近向证券交易委员会提交的文件，哈德逊湾资本管理公司在武田制药的持股价值为 3,641,000 美元。</p>
</div><p>Get <strong>Takeda Pharmaceutical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>武田制药</strong> 的提醒：</p>
</div><ul>
<li>Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师预测 Wave Life Sciences 在降息后有 85% 的上涨空间</li>
</ul>
</div><p>A number of other institutional investors have also recently bought and sold shares of the stock. Farther Finance Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the 4th quarter worth approximately $52,000. Cromwell Holdings LLC acquired a new position in Takeda Pharmaceutical in the 4th quarter worth approximately $61,000. Venturi Wealth Management LLC grew its position in Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after purchasing an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC raised its stake in Takeda Pharmaceutical by 65.0% during the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了该股票的股份。Farther Finance Advisors LLC 在第四季度将其在武田制药的持股比例提高了 123.6%。Farther Finance Advisors LLC 现在拥有 3,575 股该公司的股票，价值 47,000 美元，在此期间又购买了 1,976 股。Crowley Wealth Management Inc.在第四季度获得了武田制药的新头寸，价值约 52,000 美元。Cromwell Holdings LLC 在第四季度获得了武田制药的新头寸，价值约 61,000 美元。Venturi Wealth Management LLC 在第四季度将其在武田制药的持股比例提高了 554.7%。Venturi Wealth Management LLC 现在拥有 5,028 股该公司的股票，价值 67,000 美元，在上个季度又购买了 4,260 股。最后，Lindbrook Capital LLC 在第四季度将其在武田制药的持股比例提高了 65.0%。Lindbrook Capital LLC 现在拥有 5,151 股该公司的股票，价值 68,000 美元，在此期间又购买了 2,029 股。对冲基金和其他机构投资者持有该公司 9.17% 的股票。</p>
</div><h2>Takeda Pharmaceutical Trading Down 1.4%</h2>
<div class="lb-trans"><h2>武田制药股价下跌 1.4%</h2>
</div><p>Shares of NYSE TAK opened at $14.17 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43. The business has a 50-day moving average price of $14.86 and a two-hundred day moving average price of $14.00. The firm has a market capitalization of $45.07 billion, a PE ratio of 35.41, a PEG ratio of 0.24 and a beta of 0.26.</p>
<div class="lb-trans"><p>NYSE TAK 的股票在周二开盘价为 14.17 美元。该公司的流动比率为 1.31，速动比率为 0.72，债务与股本比率为 0.63。武田制药有限公司的股价在一年内最低为 12.58 美元，最高为 15.43 美元。该公司的 50 日移动平均价格为 14.86 美元，200 日移动平均价格为 14.00 美元。该公司的市值为 450.7 亿美元，市盈率为 35.41，市盈增长比率为 0.24，贝塔值为 0.26。</p>
</div><ul>
<li>Time to buy these 3 healthcare companies that raised revenue guidance?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是购买这三家提高收入指引的医疗公司吗？</li>
</ul>
</div><p>Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>武田制药（NYSE:TAK - 获取免费报告）最近在 5 月 8 日星期四发布了季度财报。该公司报告季度每股收益为 0.16 美元，低于市场共识预期的 0.24 美元，差距为 0.08 美元。武田制药的股本回报率为 9.39%，净利润率为 4.53%。该公司季度收入为 73.4 亿美元，而分析师预期为 80.2 亿美元。整体来看，分析师预测武田制药有限公司在当前财政年度的每股收益为 1.64 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>Separately, Morgan Stanley raised Takeda Pharmaceutical from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report on Wednesday, April 2nd.</p>
<div class="lb-trans"><p>另外，摩根士丹利在 4 月 2 日星期三的一份研究报告中将武田制药的评级从 “持平” 上调至 “增持”。</p>
</div><ul>
<li>Price Growth &amp; Yield: For That Magical Combo, Leave the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>价格增长与收益：为了那种神奇的组合，离开美国。</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Takeda Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>查看我们关于武田制药的最新股票报告</strong></p>
</div><h2>Takeda Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>武田制药公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.</p>
<div class="lb-trans"><p>武田制药有限公司从事药品的研究、开发、生产、营销和外部授权，业务遍及日本及国际市场。它在胃肠病、罕见疾病、血浆衍生疗法、免疫学、肿瘤学和神经科学等领域提供药品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Takeda Pharmaceutical</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Palantir’s Latest Deal Could Put a Freeze on Its Stock Price</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>4 Automaker Stocks React to Tariffs: Winners and Losers</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Here's Why Call Option Traders Love Dutch Bros Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过武田制药</li>
<li>每月分红股票的利弊</li>
<li>Palantir 的最新交易可能会冻结其股价</li>
<li>交易股票：相对强弱指数及其用途</li>
<li>4 家汽车制造商股票对关税的反应：赢家与输家</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>这就是为什么期权交易者喜欢 Dutch Bros 股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRBSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TAK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Takeda Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在武田制药吗？</h2>
</div><p>Before you consider Takeda Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑武田制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而武田制药并不在名单上。</p>
</div><p>While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然武田制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hudson Bay Capital Management LP 增加了对武田药品工业株式会社（NYSE:TAK）的持股